RUNX1T1 and acute myeloid leukemia: Between 01/01/2010 and 12/31/2019, 303 patients from nine centers with newly diagnosed CBF or NPM1-mutated AML (RUNX1::RUNX1T1, 19%; CBFB::MYH11, 27%; NPM1, 53%) who were in first complete remission and who had MRD monitoring after first-line intensive chemotherapy were included.